NEPHROCARE HEALTH SERV L vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of NEPHROCARE HEALTH SERV L (NEPHROPLUS) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

NEPHROPLUS logo
NEPHROCARE HEALTH SERV L
NEPHROPLUS
₹691.2+0.23%
VS
TORNTPHARM logo
TORRENT PHARMACEUTICALS L
TORNTPHARM
₹4,978+0.25%
Leads on the numbers
The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads NEPHROPLUS vs TORNTPHARM on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability03
  • Growth10
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

TORNTPHARM takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

90.23
P/E ratio
77.88
6.08
P/B ratio
18.67
0.00%
Dividend yield
0.76%
₹7.66
EPS
₹63.92

Profitability

TORNTPHARM takes 3/4

How efficiently each company turns capital and sales into profit. Higher is better.

9.06%
Return on equity
27.40%
15.00%
Return on capital even
15.00%
22.00%
EBITDA margin
33.00%
7.71%
Net margin
15.29%

Growth

NEPHROPLUS takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

31.73%
Revenue CAGR (3Y)
13.27%
—
Profit CAGR (3Y) even
19.75%

Size & financial health

TORNTPHARM takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹6,949 Cr
Market cap
₹1.90L Cr
₹999 Cr
Revenue
₹13,980 Cr
₹77 Cr
Net profit
₹2,138 Cr
0.01
Debt / equity
1.69
NEPHROCARE HEALTH SERV L
  • + ["Company has reduced debt.", "Company is almost debt free.", "Company has delivered good profit growth of 162% CAGR over last 5 years"]
  • − ["Stock is trading at 6.22 times its book value", "Though the company is reporting repeated profits, it is not paying out dividend", "Company has a low return on equity of 10.2% over last 3 years.", "Company's cost of borrowing seems high"]
TORRENT PHARMACEUTICALS L
  • + ["Company is expected to give good quarter", "Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • − ["Stock is trading at 20.4 times its book value", "Promoter holding has decreased over last quarter: -7.53%", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
NEPHROCARE HEALTH SERV L full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.